论文部分内容阅读
目的观察丁螺环酮治疗小脑性共济失调的疗效。方法小脑性共济失调患者205例,随机分为两组:对照组95例,给予常规治疗及综合康复训练;试验组110例,在对照组治疗的基础上加用丁螺环酮治疗3个月。采用世界神经病联合会国际合作共济失调量表(ICARS)评估并比较两组疗效。结果治疗前,两组患者的ICARS症状评分差异均无统计学意义(P>0.05)。治疗3个月后,两组患者的姿势和步态、动态功能、言语障碍和眼球运动障碍四项症状评分均低于治疗前(P<0.05),试验组均低于对照组(P<0.05)。治疗3个月后,试验组ICARS总分低于对照组[(21.3±11.9)分vs.(27.0±16.5)分](P<0.05)。试验组3个月治疗过程中未发现药物相关严重不良反应。结论在常规治疗及综合康复训练的基础上,加用丁螺环酮治疗能显著提高小脑性共济失调患者的短期疗效。
Objective To observe the curative effect of buspirone on cerebellar ataxia. Methods 205 patients with cerebellar ataxia were randomly divided into two groups: control group of 95 cases, given conventional therapy and comprehensive rehabilitation training; experimental group of 110 cases, in the control group based on the treatment with buspirone treatment of 3 month. The International Association of Neurological Diseases International Cooperative Ataxia Scale (ICARS) was used to evaluate and compare the efficacy of the two groups. Results Before treatment, there was no significant difference in ICARS symptom scores between the two groups (P> 0.05). After 3 months of treatment, the scores of posture and gait, dynamic function, speech impairment and eye movement disorder in both groups were lower than those before treatment (P <0.05), and the scores in the experimental group were lower than those in the control group (P <0.05 ). After 3 months of treatment, the ICARS score of the experimental group was lower than that of the control group [(21.3 ± 11.9) vs (27.0 ± 16.5) points] (P <0.05). The experimental group found no drug-related serious adverse reactions during the course of 3 months. Conclusion Buspirone can significantly improve the short-term effect of cerebellar ataxia on the basis of routine treatment and comprehensive rehabilitation training.